Clinical trials with afatinib, pyrotinib, trastuzumab emtansine, and trastuzumab deruxtecan are being evaluated for their efficacy against EGFR‐TKI‐resistant ERBB2 amplified lung cancers.39 Here, EGFR is linked to lung carcinoma.